Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 8/20 | 0.80 |
| ▸ | MEN1 | O00255 | 7/20 | 0.80 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.80 |
| ▸ | CTSB | P07858 | 1/20 | 0.80 |
| ▸ | ELANE | P08246 | 1/20 | 0.80 |
| ▸ | AKT1 | P31749 | 3/20 | 0.75 |
| ▸ | POLB | P06746 | 2/20 | 0.74 |
| ▸ | ATM | Q13315 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.74 |
| ▸ | PKM | P14618 | 3/20 | 0.70 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.61 |
| ▸ | APEX1 | P27695 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5407138 | 0.89 | MEN1 (1.00) | KMT2AMEN1KLKB1CTSBELANE | |
| Butadiazamide SCHEMBL2109869 | 0.88 | ALDH1A1 (0.69) | KMT2AMEN1KLKB1CTSBELANE | |
| SCHEMBL11893076 | 0.87 | AKT1 (0.77) | KMT2AMEN1KLKB1CTSBELANE | |
| SCHEMBL13212141 | 0.86 | KMT2A (1.00) | KMT2AMEN1KLKB1CTSBELANE | |
| Sulfaethidole SCHEMBL152872 | 0.86 | AKT1 (1.00) | KMT2AMEN1KLKB1CTSBELANE | |
| SCHEMBL14864422 | 0.85 | ATM (1.00) | KMT2AMEN1KLKB1CTSBELANE | |
| SCHEMBL30209709 | 0.85 | RECQL (0.79) | KMT2AMEN1KLKB1CTSBELANE | |
| SCHEMBL5389014 | 0.85 | ALDH1A1 (1.00) | KMT2AMEN1KLKB1CTSBELANE | |
| Sulfaethidole SCHEMBL10510090 | 0.84 | AKT1 (0.97) | KMT2AMEN1KLKB1CTSBELANE | |
| SCHEMBL5390639 | 0.84 | ALDH1A1 (0.73) | KMT2AMEN1KLKB1CTSBELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | LANDAUER, STEPHEN PAUL | 2024-10-03 | — | — | US | claimed |
| WO-2023009629-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-02-02 | — | — | WO | claimed |
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | LANDAUER, STEPHEN PAUL | 2024-10-03 | — | — | US | disclosed |
| WO-2023009629-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | THOMAS JEFFERSON UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240325340-A1 | ISOFORM SPECIFIC AGONISTS TARGETING AKT KINASE | AKT3, AKT1, AKT2 | KMT2A 2069/4885MEN1 2953/4885KLKB1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.